Medicare Law Means More Mergers In Drug Industry, Bill Drafter Predicts
Executive Summary
Some drug manufacturers may need to pursue mergers to improve their leverage to get on Medicare prescription drug plan formularies, attorney Patrick Morrisey (Sidley Austin Brown & Wood, Washington, D.C.) said
You may also be interested in...
Medicare Formularies Will Have Two Drugs Per Class; CMS To Track Atypicals
Medicare prescription drug plan formularies will have at least two drugs in each class, CMS Administrator-designate Mark McClellan says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials